Beverly D. Smolich - Concepedia

Concepedia

Author

Beverly D. Smolich

Maxygen (United States)

Also Known As

B D Smolich, B. Smolich, Beverly D Smolich, Beverly D. Smolich, Beverly Smolich

18

Publications

2.2K

Citations

16

H-Index

52

Concepts

All Affiliations

Maxygen (United States)Oregon Health & Science University University of California, Berkeley The University of Texas MD Anderson Cancer Center University of Virginia

BD

About

Beverly D. Smolich is an author at Maxygen (United States) specializing in medicine, natural sciences, and molecular genetics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	13	13	916
2	Natural Sciences	7	7	352
3	Cell Biology	6	6	583
4	Biology	4	4	139
5	Cellular Physiology	1	1	173

Beverly D. Smolich

×

17

Publications

2.2K

Citations

16

H-Index

	Year	Citations
SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo Anne-Marie O'Farrell, Tinya J. Abrams, Helene A. Yuen, Blood	2003	856
Development of SU5416, a selective small molecule inhibitor of VEGF receptor tyrosine kinase activity, as an anti-angiogenesis agent. Dirk B. Mendel, Alexander Laird, Beverly D. Smolich, PubMed Anti-angiogenesis AgentReceptor TyrosineAngiogenesisMedicineReceptor Tyrosine Kinase	2000	234
The antiangiogenic protein kinase inhibitors SU5416 and SU6668 inhibit the SCF receptor (c-kit) in a human myeloid leukemia cell line and in acute myeloid leukemia blasts Beverly D. Smolich, Helene A. Yuen, Kristina West, Blood	2001	180
Wnt family proteins are secreted and associated with the cell surface. Beverly D. Smolich, Jill A. McMahon, Andrew P. McMahon, Molecular Biology of the Cell Protein SecretionWnt Gene FamilyCellular PhysiologyTumor BiologyTranscriptional Regulation	1993	173
SU5416 and SU5614 inhibit kinase activity of wild-type and mutant FLT3 receptor tyrosine kinase Kevin Yee, A O’Farrell, Beverly D. Smolich, Blood	2002	164
Biomarker-driven therapies for previously treated squamous non-small-cell lung cancer (Lung-MAP SWOG S1400): a biomarker-driven master protocol Mary W. Redman, Vassiliki A. Papadimitrakopoulou, Katherine Minichiello, The Lancet Oncology Prognostic BiomarkersMedicineBiomarker TargetBiomarker-driven TherapiesPathology	2020	114
Expression profiling of blood samples from an SU5416 Phase III metastatic colorectal cancer clinical trial: a novel strategy for biomarker identification Samuel E. DePrimo, Lily Wong, Deepak Khatry, BMC Cancer	2003	97
Effects of SU5416, a small molecule tyrosine kinase receptor inhibitor, on FLT3 expression and phosphorylation in patients with refractory acute myeloid leukemia Anne-Marie O’Farrell, Helene A. Yuen, Beverly D. Smolich, Leukemia Research Hematological MalignancyMedicineMixed-phenotype Acute LeukemiaReceptor Tyrosine KinaseMalignant Blood Disorder	2004	76
Xenopus gamma-crystallin gene expression: evidence that the gamma-crystallin gene family is transcribed in lens and nonlens tissues. Beverly D. Smolich, Sharon K. Tarkington, Margaret S. Saha, Molecular and Cellular Biology Xenopus LaevisGeneticsLens DifferentiationMolecular GeneticsEmbryology	1994	55
EVOLUTION AND MITOCHONDRIAL DNA IN <i>NEUROSPORA CRASSA</i> John W. Taylor, Beverly D. Smolich, Georgiana May Evolution GeneticsMolecular GeneticsGenomicsPhylogenetic AnalysisPhylogenetics	1986	54

Page 1